Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms

Margaret Nieborowska-Skorska; Silvia Maifrede; Yashodhara Dasgupta; Katherine Sullivan; Sylwia Flis; Bac Viet Le; Martyna Solecka; Elizaveta Belyaeva; Lucia Kubovčáková; Morgan Nawrocki; Martin Kirschner; Huaqing Zhao; Josef T. Prchal; Katarzyna Piwocka; Alison R. Moliterno; Mariusz A. Wasik; Steffen Koschmieder; Radek C. Skoda; Tomasz Skórski

doi:10.1182/blood-2017-05-784942

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

primary MPN xenografts. In conclusion, we postulate that ruxolitinib-induced deficiencies in DSB repair pathways sensitized MPN cells to synthetic lethality triggered by PARP inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nieborowska-Skorska et al. (2017) studied this question.

synapsesocial.com/papers/6a969ec26b29a448da8238bc https://doi.org/10.1182/blood-2017-05-784942

View Full Paper

Ask AI

Bookmark

Share

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms

Ask about this paper

Abstract

Discussion

Cite This Study

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading